Overview

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina

Status:
Completed
Trial end date:
2018-09-03
Target enrollment:
Participant gender:
Summary
Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina
Details
Lead Sponsor:
Ferring Pharmaceuticals
Treatments:
Androgens
Hormones